Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1

Interventions

fludarabine 17Cyclophosphamide 15Specimen Handling 14Biopsy 12fludarabine phosphate 11Melphalan 10Cytarabine 10Busulfan 10Mycophenolic Acid 9Whole-Body Irradiation 8Tacrolimus 8venetoclax 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Injections 6Cyclosporine 6Stem Cell Transplantation 5Sirolimus 5Filgrastim 5Azacitidine 5X-Rays 4Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4CPX-351 4ruxolitinib 3Magnetic Resonance Spectroscopy 3Hematopoietic Stem Cell Transplantation 3Decitabine 3treosulfan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × quizartinib × 30 days × Clear all
NCT04128748 2026-06-02

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡